GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations.